Top global asset managers like BlackRock, 21Shares, WisdomTree, and Bitwise have opened access to Bitcoin and Ethereum exchange-traded products that are available to UK retail investors. BlackRock’s iShares Bitcoin ETF will be listed on the London Stock Exchange (LSE), with its shares physically backed by BTC and held via Coinbase. The BlackRock Bitcoin ETF has already been a massive success in the US, becoming the fastest ETF in history to approach $100 billion AUM, within 18 months of launch. Speaking ...

Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) are up on Monday after the U.K.'s Financial Conduct Authority lifted its four-year retail ban on crypto exchange-traded notes, allowing 21Shares, Bitwise, and WisdomTree to open access to British investors.FCA Opens Doors To Retail InvestorsThe move marks a milestone for U.K. digital asset regulation, expanding access to physically backed Bitcoin and Ethereum exchange-traded products (ETPs) beyond institutional buyers.Asset managers 21Shares, Bitwise, and Wis ...

A group of companies including Exxon Mobil (NYSE:XOM) and BlackRock's (NYSE:BLK) Global Infrastructure Partners have joined forces to develop a new way to measure carbon emissions of the products they make, buy and finance, Bloomberg reported Monday. The group, which also ...

Eleven retail-frindly crypto ETPs made their London debut on Monday. | Credit: Chait Goli via PExels. Key Takeaways Retail crypto ETPs hit the London Stock Exchange on Monday, Oct. 20. Asset managers catering to the U.K. market include WisdomTree, 21Shares, Bitwise, and BlackRock. As 11 ETPs make their retail debut in London, providers hope to attract investors with reduced fees. Following a recent rule change, a suite of retail-friendly exchange-traded products (ETPs) with crypto exposure hit the ...

BlackRock’s long-awaited iShares Bitcoin ETP (IB1T) made its debut on the London Stock Exchange (LSE) on Monday, allowing the United Kingdom users to be exposed to retail assets. Source: LSE The product allows retail investors to gain regulated exposure to Bitcoin without directly holding the asset. Notably, this is made possible by the Financial Conduct Authority’s (FCA) recent decision to lift its multi-year ban on crypto-based exchange-traded products. Within its first hour of trading, the physically ...

BlackRock has launched its first Bitcoin exchange-traded product for UK retail investors, opening institutional-grade crypto access to Britain's retail market amid volatile trading conditions. The iShares Bitcoin ETP began trading on the London Stock Exchange on Monday, with securities physically backed by Bitcoin held through Coinbase, as per the Financial Times report. "As the UK crypto investor base is projected to approach 4 million over the next year, today's listing of exchange-traded products like ...

Tokenization was once just a whisper in the wind. Now, it’s a scream. Investment giant BlackRock, which boasts more than $13 trillion in assets under management, has made tokenized ETFs a top priority, CEO Larry Fink confirmed on an earnings call last week. Fink, who said that the crypto industry is set to grow “rapidly,” is calling for more regulatory clarity as his firm builds up the technology required to tokenize both its ETFs and traditional securities. The move is the latest by one of the industry’s ...

BlackRock debuted a bitcoin exchange-traded product (ETP) on the London Stock Exchange on Monday, one of a number of similar offerings that started trading after the Financial Conduct Authority ended a ban on retail investment imposed in 2021. In addition to the iShares Bitcoin ETP trading under the ticker IB1T, investors also gained access to products from companies including 21Shares, WisdomTree and Bitwise, which allow retail investors to buy exposure to bitcoin through a regulated market without needi ...

公司股权变动 - 贝莱德在招商银行H股的持股比例由5.04%下降至4.92% [1] - 此次股权变动发生于10月15日 [1] - 相关信息由香港交易所披露 [1]

股价表现 - 公司股价在周五单日飙升248% 收盘报1.64美元 [1] - 受与日本中外制药合作消息推动 公司股价在过去一个月内已上涨222% [2] 合作协议核心条款 - 公司与日本中外制药达成合作 共同开发用于罕见病抗体的口服制剂 [2] - 合作协议总价值可能超过10亿美元 若所有里程碑均达成 [2] - 公司将获得1000万美元首付款 并有资格获得高达7500万美元的技术转移和开发里程碑付款 [3] - 公司还可能获得高达1亿美元的销售里程碑付款 以及未来销售额的低个位数百分比分成 [4] - 中外制药保留选择权 可在类似条款下将合作扩展至多达五个额外药物靶点 [4] 融资与机构持股 - 公司同时宣布由Samsara BioCapital领投的6030万美元私募融资 其他参与方包括RA Capital Management等多家机构 [5] - 尽管股价处于低价股水平 但公司吸引了主要机构投资者 Vanguard集团持有799,679股 BlackRock持有118,652股 [5] 技术与合作背景 - 合作代表了公司前沿的口服递送平台与中外制药开发复杂抗体专业知识的结合 [4] - 公司核心技术为RaniPill 一种可口服递送生物制剂药物以取代注射的胶囊 [2]